Capital Investment Services of America Inc. Purchases 2,630 Shares of Illumina, Inc. (NASDAQ:ILMN)

Capital Investment Services of America Inc. grew its position in Illumina, Inc. (NASDAQ:ILMN) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 82,966 shares of the life sciences company’s stock after purchasing an additional 2,630 shares during the quarter. Capital Investment Services of America Inc. owned approximately 0.05% of Illumina worth $10,820,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Illumina by 0.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 386,241 shares of the life sciences company’s stock worth $53,039,000 after buying an additional 2,240 shares in the last quarter. Norden Group LLC bought a new position in shares of Illumina in the first quarter worth $584,000. First Trust Direct Indexing L.P. bought a new stake in shares of Illumina during the first quarter valued at about $229,000. Private Advisor Group LLC lifted its stake in Illumina by 4.8% in the 1st quarter. Private Advisor Group LLC now owns 4,955 shares of the life sciences company’s stock worth $679,000 after purchasing an additional 226 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Illumina by 41.5% in the first quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock worth $422,000 after buying an additional 900 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ILMN. Royal Bank of Canada restated an “outperform” rating and set a $252.00 price target on shares of Illumina in a research report on Thursday, October 10th. TD Cowen upgraded shares of Illumina from a “hold” rating to a “buy” rating and upped their price objective for the stock from $126.00 to $144.00 in a report on Wednesday, August 14th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Scotiabank reduced their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Finally, Citigroup raised their price objective on shares of Illumina from $140.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and an average target price of $154.33.

Illumina Stock Up 3.1 %

ILMN stock traded up $4.57 on Monday, hitting $154.33. 1,055,491 shares of the company’s stock were exchanged, compared to its average volume of 1,982,080. The stock has a market cap of $24.58 billion, a P/E ratio of -7.82 and a beta of 1.13. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $155.37. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a 50 day moving average price of $135.93 and a two-hundred day moving average price of $122.39.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s revenue was down 5.4% compared to the same quarter last year. As a group, equities research analysts expect that Illumina, Inc. will post 3.63 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.